Please add info@sitcancer.org to your safe senders list.
March 2016 – In this Issue
Funding Opportunity | Education & Events | Cancer Immunotherapy 101 | SITC 2016
Membership | Publications & Resources | Careers
A Message from the President
Dear Colleagues,
As we come to a close on the first quarter of 2016, I continue to be amazed by the number of people and organizations that have come together in order to increase the knowledge and reach of cancer immunotherapy. In response to the unprecedented needs in the field, the Society of Immunotherapy of Cancer (SITC) has continued its commitment to cancer immunotherapy education, and has increased its involvement cancer immunotherapy education programs worldwide.
As the world’s leading member-driven society dedicated to professionals working in the field of cancer immunotherapy, we work hard to ensure all of our members—students, clinicians, scientists, nurses, pharmacists, industry professionals and government representatives alike—have access to and are engaged in the implementation of timely, cutting-edge translational clinical research in cancer immunotherapy.
We at SITC look forward to working with others in the field through education, events and continued collaboration. On behalf of the society, I thank you for your efforts to advance the cancer immunotherapy field. Together, we can one day make the word “cure” a reality for cancer patients everywhere.
Best regards,
Howard L. Kaufman, MD, FACS
SITC President
Funding Opportunity
2016 NCI Immunotherapy Fellowship - Deadline Extended!
Cosponsored
by the National Cancer Institute (NCI) and the Society for
Immunotherapy of Cancer (SITC) and made possible in part by an
educational grant from EMD-Serono
SITC
is pleased to announce the extension of the National Cancer Institute
(NCI) Immunotherapy Fellowship application deadline. Applications will
be accepted now through April 21, 2016.
This training program is designed for physicians who have completed a medical oncology fellowship program in the United States and who seek specialized training in immunotherapy with clinical trials and clinical trial development. The 1-year program at the CCR in Bethesda, Maryland, allows the fellow to have exposure to multiple clinical immunotherapeutic approaches, and also to key opinion leaders in the field of clinical immunotherapy. In addition, the fellowship provides opportunities to understand how to design, write, and run clinical trials, how to treat patients, how to manage toxicities, as well as opportunities to work with multiple experimental agents.Get more information, including eligibility requirements, here.
Radiation and Immunotherapy Leadership Summit
Cosponsored with the National Cancer Institute
Thursday, March 31, 2016 • 9 a.m. – 5 p.m.
Bethesda North Marriott Hotel & Conference Center • Bethesda, Maryland
This free, one-day summit is intended for leaders in the fields of radiation, immunotherapy and combination treatments. The goal of this meeting is to discuss provocative questions surrounding the use of radiation and immunotherapy, in order to build consensus that generates a white paper report of recommendations and focus areas. Learn more and register here.
Immunotherapy Biomarkers 2016: Overcoming the Barriers
Cosponsored with the National Cancer Institute
Friday, April 1, 2016 • 8 a.m. – 5 p.m.
National Institutes of Health Campus • Bethesda, Maryland
Individuals
from academia, biotech, pharma, government, researchers, and early
career scientists have the opportunity to hear updates on the immune
biomarker research, review the state of the art, explore current hurdles
to further success and consider recommendations during this one day
scientific program. Through
didactic sessions and panel discussions, SITC Immune Biomarkers Task
Force working group members and National Cancer Institute Center for
Cancer Research faculty will facilitate scientific exchange and solicit
stakeholder participation to promote successful immune biomarker
research. Learn more about the program and register here before the March 24 deadline.
Other Upcoming Collaborative Programs
- Community Oncology Conference
April 14-15, 2016 • Orlando, Florida
Presented by the Community Oncology Alliance (COA) in collaboration with the Society for Immunotherapy of Cancer
- Tumor Immunology Meets Oncology (TIMO) XII
April 28-30, 2016 • Halle (Saale), Germany
Presented by the Martin Luther University Halle-Wittenberg in collaboration with the Society for Immunotherapy of Cancer
- COS-CAHON-SITC Workshop on Cancer Immunotherapy
April 30, 2016 • Taipei, Taiwan
Presented by The Chinese Oncology Society in collaboration with the Chinese American Hematologist and Oncologist Network and the Society for Immunotherapy of Cancer
- Overcoming Failure of Immune Checkpoint Inhibition in Patients With Cancer
May 15, 2016 • Seattle, Washington
Presented by the American Association of Immunologists (AAI) in collaboration with the Society for Immunotherapy of Cancer
Find more information on these and other collaborative programs here.
Two Locations Now Open for Registration
Part of the Advances in Cancer ImmunotherapyTM series, Cancer Immunotherapy 101 is an introductory, CME- and CE-certified program designed to provide clinical oncologists, nurses, pharmacists, and the entire team involved in treating cancer patients a greater understanding of cancer immunotherapies, their therapeutic effectiveness, and the appropriate selection and management of patients.
- Milwaukee, Wisconsin - Thursday, April 7
Hilton Milwaukee City Center
Organized by University of Wisconsin Carbone Cancer Center representatives, Christian Capitini, MD; Paul M. Sondel, MD, PhD; and Anne Wolvin, RN, OCN
Register online by April 4 to secure a seat!
- Chicago, Illinois - Thursday, June 23
Hyatt Regency McCormick Place
Organized by Linda A. Janisch, APN (University of Chicago); Timothy M. Kuzel, MD (Northwestern University); and Jason J. Luke, MD, FACP (University of Chicago)
Register by June 2 for best rates!
Can't make it to either location? More dates and locations are available! Share the series flyer with your network to promote cancer immunotherapy education nationwide.
November 9-13, 2016 
Gaylord National Hotel & Convention Center
National Harbor, Maryland
Mark your calendars for the upcoming SITC 31st Annual Meeting & Associated Programs! Known as the premier destination for scientific exchange, education and networking in the cancer immunotherapy field, this is the conference you don't want to miss. Look for an email in April for information on abstract submission dates, housing, registration, exhibiting and more! Click here to learn more.
31st Annual Meeting & Associated Programs will include:
- 31st Annual Meeting with Keynote Addresses to be given by Ira Mellman, PhD and the 2016 Richard V. Smalley, MD Memorial Award Recipient Suzanne L. Toplaian, MD
- Workshop on Challenges, Insights and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy
- Primer on Tumor Immunology and Cancer immunotherapy™
- Value of Cancer Immunotherapy Summit (Organized in Collaboration with the American Society of Clinical Oncology (ASCO))
- Continuing education credits for physicians, pharmacists and nurses
Membership Makes a Difference
Not a member yet? Join today!
SITC is the world’s leading member-driven society dedicated to professionals working in the field of cancer immunotherapy. As a member, you will join a growing network of nearly 1,300 basic and translational scientists, practitioners, healthcare professionals, government leaders, and industry professionals worldwide.
There are several membership categories including: Regular, Affiliate, Allied Health, Emeritus, Nurse and Physician Extender, Patient and Patient Advocate, Pharmacist, and Scientist-in-Training/Student 
memberships. To learn more about these categories, and to apply, visit the Membership page.
Membership Benefits Include:
- Discounted registration rates on all SITC programs
- Eligibility to apply for SITC fellowships and grants, available exclusively to SITC members
- Free access to SITC "Members Only" section, including meeting slides and other online resources
- Free access to SITC's online member directory
- Waived article processing charges (a $2,500 USD savings) for SITC’s open access journal, the Journal for ImmunoTherapy of Cancer (JITC)
- ... and much more!
Do You Love Being a Part of SITC? Connect-a-Colleague!
New members often join SITC because a current member has invited them.
Please encourage your colleagues, including nurses, pharmacists, and
students, to become official SITC members by sending personalized
invitations with our online tool or have the people you invite list your name on their membership applications. If each SITC member recruits two others, we could quickly grow to 3,000 members!
Top referrers will receive recognition for their efforts.
Publications & Resources
Journal for ImmunoTherapy of Cancer, the Resource for Cutting-Edge Science in the Field
Journal for ImmunoTherapy of Cancer (JITC)
is SITC's official open access, peer-reviewed journal. It encompasses
all aspects of tumor immunology and cancer immunotherapy, from basic
research to clinical application. As the global voice of the Society,
JITC is the resource for SITC publications and also serves as a targeted
outlet for publication of original research articles, literature
reviews and position papers.
Additionally, JITC features monthly technology primers
produced by the SITC Immune Biomarkers Task Force. A hot topic in the
field, these papers examine the latest in biomarker technologies for
cancer immunotherapy. Access the articles here, and join us in Bethesda, Maryland on April 1 for Immunotherapy Biomarkers 2016: Overcoming the Barriers educational seminar held at the NCI.
Interested in publishing in JITC? SITC members receive waived article processing charges for papers accepted through 2016. Submit your manuscript here.
JITC Now Discoverable in Five Major Indexing Databases!
In addition to being indexed in PubMed, PubMed Central, the Directory of Open Access Journals (DOAJ),and Thomson Reuters’ Emerging Sources Citation Index (ESCI), we are pleased to announce that the Journal has been accepted for indexing in Elsevier’s Scopus database. Currently used by over 3,000 academic, government, and corporate institutions, Scopus delivers a comprehensive overview of the world's research output in the fields of science, technology, medicine, social sciences, and arts and humanities.
JITC content will be available in Scopus within the next few weeks and the content will be indexed retroactively, meaning that all articles dating to the first issue will be included. This increased discoverability of JITC’s outstanding content speaks to its emergence as an eminent vehicle for publishing the most important content in the cancer immunotherapy field.
Latest Opportunities from SITC's Job Board
Immuno-oncology Scientists (multiple positions)
Pfizer - La Jolla
Post-doctoral Fellow
The University of New Mexico Comprehensive Cancer Center - Alburquerque, New Mexico
Principal Scientist/Associate Director, Immnuo-Oncology
Onkaido - Cambridge, Massachutes
If you are interested in posting an open position to SITC's job board, please reference this agreement form for posting criteria or contact SITC at info@sitcancer.org.
ADVERTISEMENT
Society for Immunotherapy of Cancer (SITC)
555 East Wells Street, Suite 1100 | Milwaukee, Wisconsin 53202-3823 USA
Phone: +1 414 271 2456 | Email: info@sitcancer.org
© 2016 Society for Immunotherapy of Cancer
Join us on:
If you do not wish to be included in our mailing list, please forward this message to info@sitcancer.org with the word "Remove" in the subject line.
Please add info@sitcancer.org to your safe senders list.